9
Participants
Start Date
April 8, 2021
Primary Completion Date
November 30, 2022
Study Completion Date
November 30, 2022
RTX-321
RTX-321 monotherapy
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
UPMC Hillman Cancer Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Virginia Cancer Specialists, Fairfax
University of Alabama, Birmingham
Sarah Cannon Research Institute, Nashville
Washington University, St Louis
OU Health Stephenson Cancer Center, Oklahoma City
University of Colorado Cancer Center, Aurora
The Angeles Clinic & Research Institute, Los Angeles
Lead Sponsor
Rubius Therapeutics
INDUSTRY